---
kind: "section"
citation: "42 U.S.C. § 300cc–17"
title: "42"
title_heading: "The Public Health and Welfare"
number: "300cc–17"
heading: "Information services"
release: "119-102"
date: "2026-07-12"
url: "https://uscodex.org/usc/42/300cc-17"
units:
  - "Chapter 6A — Public Health Service"
  - "Subchapter XXI — Research with Respect to Acquired Immune Deficiency Syndrome"
  - "Part B — Research Authority"
---

# §300cc–17. Information services

- (a) **Establishment of program—** The [Secretary](/usc/42/201.md?p=c) shall establish, maintain, and operate a [program](/usc/42/274l–1.md?p=4) with respect to information on research, [treatment](/usc/42/11851.md?p=11), and prevention activities relating to infection with the etiologic agent for acquired immune deficiency syndrome. The [program](/usc/42/274l–1.md?p=4) shall, with respect to the [agencies](/usc/42/8262.md?p=1) of the Department of Health and Human [Services](/usc/42/201.md?p=a), be integrated and coordinated.
- (b) **Toll-free telephone communications for health care entities—**
  - (1) After consultation with the [Director](/usc/42/11851.md?p=5) of the Office of AIDS Research, the [Administrator](/usc/42/300bb–8.md?p=4) of the Health Resources and [Services](/usc/42/201.md?p=a) Administration, and the [Director](/usc/42/11851.md?p=5) of the Centers for Disease Control and Prevention, the [Secretary](/usc/42/201.md?p=c) shall provide for toll-free telephone communications to provide medical and technical information with respect to acquired immune deficiency syndrome to health care professionals, allied [health care providers](/usc/42/300aa–33.md?p=1), and to professionals providing emergency health [services](/usc/42/201.md?p=a).
  - (2) Information provided pursuant to [paragraph (1)](#b-1) shall include—
    - (A) information on prevention of exposure to, and the transmission of, the etiologic agent for acquired immune deficiency syndrome; and
    - (B) information contained in the data banks established in subsections [(c)](#c) and [(d)](#d).
- (c) **Data bank on research information—**
  - (1) After consultation with the [Director](/usc/42/11851.md?p=5) of the Office of AIDS Research, the [Director](/usc/42/11851.md?p=5) of the Centers for Disease Control and Prevention, and the National Library of Medicine, the [Secretary](/usc/42/201.md?p=c) shall establish a data bank of information on the results of research with respect to acquired immune deficiency syndrome conducted in the United States and other countries.
  - (2) In carrying out [paragraph (1)](#c-1), the [Secretary](/usc/42/201.md?p=c) shall collect, catalog, store, and disseminate the information described in such paragraph. To the extent practicable, the [Secretary](/usc/42/201.md?p=c) shall make such information available to researchers, physicians, and other appropriate individuals, of countries other than the United States.
- (d) **Data bank on clinical trials and treatments—**
  - (1) After consultation with the Commissioner of Food and [Drugs](/usc/42/11851.md?p=4), the AIDS Research [Advisory Committee](/usc/42/17061.md?p=2) established under [section 300cc–3 of this title](/usc/42/300cc–3.md), and the [Director](/usc/42/11851.md?p=5) of the Office of AIDS Research, the [Secretary](/usc/42/201.md?p=c) shall, in carrying out [subsection (a)](#a), establish a data bank of information on clinical trials and [treatments](/usc/42/11851.md?p=11) with respect to infection with the etiologic agent for acquired immune deficiency syndrome (hereafter in this section referred to as the “Data Bank”).
  - (2) In carrying out [paragraph (1)](#d-1), the [Secretary](/usc/42/201.md?p=c) shall collect, catalog, store, and disseminate the information described in such paragraph. The [Secretary](/usc/42/201.md?p=c) shall disseminate such information through information systems available to individuals infected with the etiologic agent for acquired immune deficiency syndrome, to other members of the public, to [health care providers](/usc/42/300aa–33.md?p=1), and to researchers.
- (e) **Requirements with respect to data bank on clinical trials and treatments—** The Data Bank shall include the following:
  - (1) A registry of clinical trials of experimental [treatments](/usc/42/11851.md?p=11) for acquired immune deficiency syndrome and related illnesses conducted under [regulations](/usc/42/201.md?p=d) promulgated pursuant to [section 355 of title 21](/usc/21/355.md) that provides a description of the purpose of each experimental [drug](/usc/42/11851.md?p=4) protocol either with the consent of the protocol sponsor, or when a trial to test efficacy begins. Information provided shall include eligibility criteria and the location of trial sites, and must be forwarded to the Data Bank by the sponsor of the trial not later than 21 days after the approval by the Food and [Drug](/usc/42/11851.md?p=4) Administration.
  - (2) Information pertaining to experimental [treatments](/usc/42/11851.md?p=11) for acquired immune deficiency syndrome that may be available under a [treatment](/usc/42/11851.md?p=11) investigational new [drug](/usc/42/11851.md?p=4) application that has been submitted to the Food and [Drug](/usc/42/11851.md?p=4) Administration pursuant to part 312 of title 21, Code of Federal [Regulations](/usc/42/201.md?p=d). The Data Bank shall also include information pertaining to the results of clinical trials of such [treatments](/usc/42/11851.md?p=11), with the consent of the sponsor, of such experimental [treatments](/usc/42/11851.md?p=11), including information concerning potential toxicities or adverse effects associated with the use or administration of such experimental [treatment](/usc/42/11851.md?p=11).

## Source credit

(July 1, 1944, ch. 373, title XXIII, § 2317, as added Pub. L. 100–607, title II, § 201(4), Nov. 4, 1988, 102 Stat. 3071; amended Pub. L. 100–690, title II, § 2617(c), Nov. 18, 1988, 102 Stat. 4240; Pub. L. 102–531, title III, § 312(d)(19), Oct. 27, 1992, 106 Stat. 3505; Pub. L. 103–43, title XX, § 2008(d)(4), June 10, 1993, 107 Stat. 212.)

## Notes

### Editorial Notes

### Amendments

1993—Subsec. (d)(1). Pub. L. 103–43 substituted “AIDS Research Advisory Committee established under section 300cc–3 of this title” for “Clinical Research Review Committee”.

1992—Subsecs. (b)(1), (c)(1). Pub. L. 102–531 substituted “Centers for Disease Control and Prevention” for “Centers for Disease Control”.

1988—Subsec. (e). Pub. L. 100–690 substituted “data bank on clinical trials and treatments” for “data bank” in heading.

### Statutory Notes and Related Subsidiaries

### Effective Date of 1988 Amendment

Amendment by Pub. L. 100–690 effective immediately after enactment of Pub. L. 100–607, which was approved Nov. 4, 1988, see section 2600 of Pub. L. 100–690, set out as a note under section 242m of this title.